An investigation for investors in NASDAQ:JNP shares was announced over possible securities laws violations by Juniper Pharmaceuticals and certain of its directors and officers.
Investors who purchased shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP), have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Juniper Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Juniper Pharmaceuticals Inc reported that its annual Total Revenue rose from $32.46 million in 2014 to $37.56 million in 2015 while its Net Income of $3.39 million in 2014 declined to a Net loss of $2.13 million.
On October 24, 2016, Juniper Pharmaceuticals Inc stated in a regulatory filing that its annual statements for 2013 to 2015 as well as its statements for the quarters ended March 31 and June 30, 2016, should no longer be relied upon. Juniper Pharmaceuticals Inc will have to restate its financial statements due to revenue-recognition errors related to a supply agreement with an affiliate of Germany’s Merck KGaA.
Shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP) closed on November 4, 2016 at $5.40 per share.
Those who purchased NASDAQ:JNP shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego